Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $9.5 million.

  • Phathom Pharmaceuticals' Gains from Investment Securities rose 4657.52% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 4657.52%. This contributed to the annual value of $6.2 million for FY2024, which is 3537.26% up from last year.
  • Phathom Pharmaceuticals' Gains from Investment Securities amounted to $9.5 million in Q3 2025, which was up 4657.52% from $9.7 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $9.7 million during Q2 2025, with a 5-year trough of -$5.3 million in Q4 2023.
  • Moreover, its 4-year median value for Gains from Investment Securities was $5.6 million (2022), whereas its average is $3.4 million.
  • Per our database at Business Quant, Phathom Pharmaceuticals' Gains from Investment Securities tumbled by 254626.87% in 2023 and then surged by 92029.03% in 2024.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Gains from Investment Securities stood at -$201000.0 in 2022, then crashed by 2546.27% to -$5.3 million in 2023, then surged by 83.15% to -$896000.0 in 2024, then surged by 1154.95% to $9.5 million in 2025.
  • Its Gains from Investment Securities stands at $9.5 million for Q3 2025, versus $9.7 million for Q2 2025 and -$1.8 million for Q1 2025.